Cogent Biosciences
Update in progressCOGT (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cogent Biosciences, Inc. is a clinical-stage biotech focused on precision therapies for genetically defined diseases. Its lead, bezuclastinib (CGT9486), is a Phase 3 selective KIT inhibitor targeting KIT D816V and KIT exon 17 mutations in systemic mastocytosis and advanced GIST. Other programs include CGT4859 (FGFR2 inhibitor, Phase 1, FGFR mutations including cholangiocarcinoma), CGT4255 (ErbB2 mutant program), and CGT6297 (PI3Ka inhibitor). The company is licensed to Plexxikon for bezuclastinib and is based in Waltham, Massachusetts.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.37
- Governance
- -0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Andrew R. Robbins M.B.A.
- Employees258
- Websitewww.cogentbio.com
Identifiers
- ISINUS19240Q2012
- FIGIBBG007DHZQR7
- CUSIP19240Q201
- CIK0001622229